An Open-Label, Expanded Access Study of Cabozantinib (XL184) in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer

Trial Profile

An Open-Label, Expanded Access Study of Cabozantinib (XL184) in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Jan 2013

At a glance

  • Drugs Cabozantinib (Primary)
  • Indications Thyroid cancer
  • Focus Therapeutic Use
  • Sponsors Exelixis
  • Most Recent Events

    • 15 Jan 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 06 Jan 2013 Planned end date (30 Jun 2013) added as reported by Oregon Health and Science University Institutional Review Board.
    • 06 Jan 2013 New source identified and integrated (Oregon Health and Science University Institutional Review Board; IRB00008671).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top